AcronymDefinition
AHRQAgency for Healthcare Research and Quality
ANOVAAnalysis of variance
AUCArea under the receiver-operating-characteristic curve
BCPBreast Cancer Profiling
BCTBreast conserving therapy
BIGBreast International Group
BRCABreast cancer gene
CCDCharge Coupled Devices
CDCCenters for Disease Control and Prevention
cDNAComplementary DNA
CENTRALThe Cochrane Central Register of Controlled Trials
CIConfidence Interval
CLIAClinical Laboratory Improvement Act
CMTPCenter for Medical Technology Policy
CRComplete response
CTCycle threshold
CVCoefficient of variation
DFSDisease free survival
DNADeoxyribonucleic acid
DRFSDistant recurrence-free survival
EGAPPEvaluation of Genomic Applications in Practice and Prevention
EPCThe Evidence-based Practice Center
EREstrogen receptor
FDAFood and Drug Administration
FFPEFormalyn-fixed paraffin-embedded
FISHFluorescent in situ hybridization
FRETFörster Resonance Energy Transfer
GEPGene expression profiling
HER2Human epidermal growth factor receptor 2
HRHormone Receptors
IHCImmunohistochemical
INTItalian National Cancer Institute of Milan, Italy
IVDMIAsIn Vitro Diagnostic Multivariate Index Assays
JHUJohns Hopkins University
LCMLaser-capture micro dissected
LMCLaser micro-dissection
LODLimit of detection
LOQLimit of quality
MeSHMedical subject heading
MIAMEMinimum Information About a Microarray Experiment
MINDACTMicroarray for Node-Negative Disease may Avoid Chemotherapy
mRNAMessenger ribonucleic acid
NCCNNational Comprehensive Cancer Network
NCCTGNorth Central Cancer Treatment Group
NCINational Cancer Institute
NHGNottingham Histologic Grade
NIHNational Institutes of Health
NPINottingham Prognostic Index
NSABPNational Surgical Adjuvant Breast and Bowel Project
OROdds Ratio
OSOverall survival
OVIDOffice of In Vitro Diagnostic evaluation and Safety
pCRComplete pathological response
PCRPolymerase chain reaction
PDProgressive disease
PFSProgression free survival
PMAPre-Market Approval
PRProgesterone receptor
PRPartial response
QALYQuality-adjusted life-year
RCTRandomized Controlled Trial
RECISTResponse Evaluation Criteria in Solid Tumors
REMARKReporting recommendations for tumour MARKer prognostic studies
RFSRelapse Free Survival
RNARibonucleic acid
ROCReceiver operating characteristic
RRRelative risk
RSRecurrence Score
RT-PCRreverse transcriptase polymerase chain reaction
SDStandard deviation
SNPSingle nucleotide polymorphisms
STARDStandards for Reporting of Diagnostic Accuracy
TAILORxTrial Assigning Individualized Options for Treatment
TBCIThe North American Breast Cancer Intergroup
TRANSBIGTranslating molecular knowledge into early breast cancer management: building on the BIG (Breast International Group) network for improved treatment tailoring
TTMTime to distant metastases
VEGFVascular epithelial growth factor

From: Appendix A: List of Acronyms

Cover of Impact of Gene Expression Profiling Tests on Breast Cancer Outcomes
Impact of Gene Expression Profiling Tests on Breast Cancer Outcomes.
Evidence Reports/Technology Assessments, No. 160.
Marchionni L, Wilson RF, Marinopoulos SS, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.